Bruce Beutel

Bruce Beutel, Ph.D. is a Venture Partner of the Qiming U.S. Healthcare Fund. Previously, he served as Chief Operating Officer and Chief Business & Strategy Officer at Dewpoint Therapeutics, Chief Business Officer at SQZ Biotechnologies, and Executive Director, Business Development at Merck.

He currently serves as an Independent Director on the Boards of GRO Biosciences and Boston Immune Technologies & Therapeutics.

Bruce received his B.A. in Biology from the University of Chicago and his Ph.D. in Molecular Biology from the University of Wisconsin-Madison in the lab of M. Thomas Record, Jr.